Cannabis Poland SA
WSE:CBD
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
This alert will be permanently deleted.
Cannabis Poland SA
Cannabis Poland SA engages in the production and distribution of cannabinoid vaporization equipment and oils. The company is headquartered in Warsaw, Woj. Mazowieckie. The company went IPO on 2013-04-09. The firm focuses on operating in the field of production and sale of pharmaceutical and medical products, with the main focus on vaporization products containing cannabinoids manufactured from cannabis. The firm also expands its activity to include other products than pharmaceuticals, such as cosmetics, oils containing cannabinoids for human and animals and photovoltaic cells. The firm is engaged in research and development of a Cannabidiol (CBD)/ Tetrahydrocannabinol-based (THC-based) pharmaceutical for use in the treatment of seizures associated with drug-resistant epilepsy.
Cannabis Poland SA engages in the production and distribution of cannabinoid vaporization equipment and oils. The company is headquartered in Warsaw, Woj. Mazowieckie. The company went IPO on 2013-04-09. The firm focuses on operating in the field of production and sale of pharmaceutical and medical products, with the main focus on vaporization products containing cannabinoids manufactured from cannabis. The firm also expands its activity to include other products than pharmaceuticals, such as cosmetics, oils containing cannabinoids for human and animals and photovoltaic cells. The firm is engaged in research and development of a Cannabidiol (CBD)/ Tetrahydrocannabinol-based (THC-based) pharmaceutical for use in the treatment of seizures associated with drug-resistant epilepsy.
